Integrity Alliance LLC. Takes Position in Zoetis Inc. $ZTS

Key Points

• Integrity Alliance LLC has acquired 3,258 shares of Zoetis Inc., valued at approximately $536,000, during the first quarter.
• Zoetis reported $1.76 earnings per share for the quarter, surpassing analysts' expectations of $1.62, alongside a revenue of $2.46 billion.
• Analysts have varied ratings on Zoetis, with five rating it a Buy and four issuing a Hold rating, and the consensus price target is $200.88.

Integrity Alliance LLC. bought a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,258 shares of the company's stock, valued at approximately $536,000.

Other hedge funds have also bought and sold shares of the company. Portside Wealth Group LLC boosted its stake in Zoetis by 24.7% during the first quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock worth $5,550,000 after acquiring an additional 6,672 shares in the last quarter. Tandem Investment Advisors Inc. boosted its stake in Zoetis by 100.3% during the first quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock worth $65,140,000 after acquiring an additional 198,089 shares in the last quarter. Flagship Harbor Advisors LLC boosted its stake in Zoetis by 31.2% during the first quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock worth $1,217,000 after acquiring an additional 1,760 shares in the last quarter. Horizon Financial Services LLC bought a new stake in Zoetis during the first quarter worth about $380,000. Finally, Sage Rhino Capital LLC boosted its stake in Zoetis by 117.6% during the first quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock worth $1,155,000 after acquiring an additional 3,791 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Down 1.5%

Shares of Zoetis stock opened at $148.33 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock has a market capitalization of $65.74 billion, a PE ratio of 25.53, a price-to-earnings-growth ratio of 2.42 and a beta of 0.89. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The company has a 50-day simple moving average of $152.32 and a two-hundred day simple moving average of $157.31.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analysts Set New Price Targets

ZTS has been the topic of several research reports. Argus reissued a "buy" rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Piper Sandler lifted their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.